Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed to treat conditions such as arthritis and other musculoskeletal disorders in elderly patients. The usefulness of NSAIDs is, however, often limited by their associated gastrointestinal (GI) toxicity [1, 2] . Elderly patients taking long-term NSAIDs therapy are a particularly high-risk group for NSAIDs-related GI injury [3, 4] .
NSAIDs-related GI injury is mainly a consequence of systemic inhibition of GI mucosal cyclooxygenase (COX) activity, which reduces levels of mucosa-protective prostaglandins (PG), for example prostaglandin E 2 (PGE2), rather than a result of topical epithelial injury [5] [6] [7] . Inhibition of the two isozymes of COX, COX-1 and COX-2, is important in the pathogenesis of NSAIDs-related gastric injury [6] . COX-1 is a constitutive enzyme expressed in most cells of the body, including the stomach [6] . In contrast, COX-2 is an inducible enzyme, with increased expression in response to bacterial polysaccharides and proinflammatory cytokines [6] . Although non-selective NSAIDs (e.g., indomethacin) exert their GI ulcerogenic effects mainly through COX-1 inhibition, the GI ulcerogenic effects of NSAIDs require inhibition of both COX-1 and COX-2 [7, 8] . Mucosa-protective PGs (e.g., PGE 2 ) contribute to gastric mucosal defense by reducing gastric acid secretion and by their nonantisecretory effects referred to as ''cytoprotection'' (e.g., stimulation of bicarbonate and glycoprotein secretion, increase in mucosal blood flow, among others) [9, 10] . It has been suggested that nitric oxide (NO) is the crucial intermediate in PGE 2 -mediated cytoprotection [11] . Hence, deficiency in mucosa-protective PGs or NO because of NSAIDs use is associated with compromise of gastric mucosal defense. Mechanisms independent of COX inhibition are also implicated in NSAIDs-related gastric injury. NSAIDs may also produce gastric mucosal injury by interfering with growth factors (e.g., TGF-b, TGF-a) and other mediators responsible for epithelial restitution and adaptive protection (e.g., trefoil family peptides) [12, 13] . Reactive oxygen species and apoptosis are also implicated in indomethacin-induced gastric injury [14] .
Why aging stomachs are at greater risk of NSAIDsrelated injury is still poorly understood. Data from outcome studies have identified advanced age as one of the major risk factors for NSAIDs-related upper GI injury [1] , possibly because of the finding that the aging gastric mucosa has reduced capacity for repair. A recent study investigating the effect of reactive oxygen species, apoptosis, and angiogenesis on the aging stomach has shown that aging gastric mucosa is gradually replaced by connective tissue, thus impairing gastric mucosal protection [15] . In rats of advanced age, angiogenesis is reduced as a result of reduced expression of VEGF and overexpression of PTEN [16] . Thus, reduction in mucosal defense mechanisms characteristic of the aging stomach may increase susceptibility to NSAIDs-related mucosal injury, although the underlying molecular pathogenesis remains poorly understood.
In this issue of Digestive Diseases and Sciences, Hong et al. [17] report investigation of potential molecular mechanisms behind the increased susceptibility of the aging stomach to indomethacin-induced injury. The authors hypothesize that upregulation of pro-inflammatory mediators in old stomachs increases their susceptibility to indomethacin-induced injury compared with young stomachs. When the same oral dose of indomethacin was administered to young (6 weeks) and old (60 weeks) rats, significantly greater gastric mucosal damage was observed in old rat stomachs. Before administration of indomethacin, levels of several inflammatory mediators (COX-2, iNOS, HIF-1a, and 5-LOX), inflammatory cytokines (TNF-a, IL1b, IL-6, IL-8, and IFN-c), inflammatory chemokines (MIP-1a, MIP-1b, MCP-1, and RANTES), adhesion molecules (ICAM-1, VCAM-1, and VGEF), proteases (MMP-2 and MMP-9), total oxidants, and apoptotic executors (caspase-3 Bax) were already significantly higher in the stomachs of old rats; these levels were further increased after indomethacin administration. The authors concluded that redox activation and an increase in pro-inflammatory mediators are likely mechanisms behind the increased vulnerability of aging stomachs to NSAIDs-related injury.
Yet, this study also reported findings that challenge our current belief that PGE 2 deficiency is the main cause of NSAIDs-related gastric injury. In particular, initially, i.e. before administration of indomethacin, Hong et al. found no difference between PGE 2 levels in young and old rat stomachs; subsequently, i.e. after indomethacin administration, they observed a significant increase in PGE 2 levels in old rat stomachs. How can we explain these discrepancies? For the first finding, perhaps the actual decline in age-related gastric mucosal defense may not be entirely PGE 2 -dependent. It is possible that additional events (e.g., replacement of mucosal tissue by connective tissue and reduced angiogenesis) may be more important in the impaired mucosal defense of aging stomachs [15, 16] . For the second finding, the increase in PGE 2 level may be related to the known observation of upregulation of COX-2 expression after NSAIDs-related inhibition of COX-1 [18] . Moreover, the increase in PGE 2 12 h after indomethacin administration may be a transient phenomenon in the dynamic process of NSAIDs-related gastric injury. Whether or not persistent elevation of PGE 2 level occurs has not been addressed. Further research is needed to resolve some of the uncertainties raised by this study and to better elucidate the actual sequence of molecular events in NSAIDs-related gastric injury.
